M. Webster

Occlusion of a Giant Saphenous Vein Graft Aneurysm Using Distal Coil Embolisation and a Proximal Vascular Plug

An asymptomatic giant true saphenous vein graft aneurysm was successfully occluded by percutaneous distal coil embolisation combined with deployment of a proximal Amplatzer vascular occlusion plug. The aneurysm cavity was excluded from both antegrade flow via the aortosaphenous anastamosis and retrograde flow via the distal left anterior descending coronary artery (supplied by a left internal mammary artery graft), to reduce the risk of subsequent aneurysm rupture.

Assessing Surgical Risk for Aortic Valve Surgery in Octogenarians: A Comparison of Three Risk Calculators

(p 35 were 0.3, 0 and −0.05 respectively. Variation in measurements was greater for WC (IQR −3% to 4%) than BMI (IQR −2% to 3%). Conclusion: There is no change in BMI or waist circumference at follow-up following admission with acute coronary syndrome. The increased variation in waist circumferencemeasurement compared to BMI likely reflects differences in measurement technique than true weight change. Patients following ACS need improved education strategies stressing the importance of weight loss. http://dx.doi.org/10.1016/j.hlc.2013.04.068

Percutaneous Aortic Valve Replacement Using The Corevalve® Revalving System For Severe Aortic Stenosis (AS)—Initial Mercy Hospital Experience

37 PERCUTANEOUS AORTIC VALVE REPLACEMENT USING THE COREVALVE® REVALVING SYSTEM FOR SEVERE AORTIC STENOSIS (AS)—INITIAL MERCY HOSPITAL EXPERIENCE ME Legget 1,2,∗, JA Ormiston1,2, JT Stewart 1,2, MWI Webster 1, C Kruger 1, N Middleton1, PJ Raudkivi 1, DA Haydock1 1Mercy Angiography, Auckland, New Zealand 2 Auckland Heart Group, Auckland, New Zealand Background: Surgical aortic valve replacement is the standardof care for symptomatic patients (pts)with severe AS.For inoperableorveryhighriskpatients,percutaneous aortic valve replacement (PAVR) is now an option. This study summarises our single centre experience in the first 16 ptswho underwent PAVRusing aCoreValve® revalving system, consisting of a self-expanding multi-level nitinol frame with a tri-leaflet porcine pericardial valve. Methods: Patient assessment included clinical assessment, coronary and peripheral angiography, aortography, and echocardiography. Amultidisciplinary team assessed appropriateness of PAVR. Implantation was performed under general anaesthesia with haemostasis at the 18F access site achieved percutaneously. Results: There were no cardiac deaths or strokes within the first month after PAVR (n= 11). No embolic episodes o 2 n o